The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Varenicline, an α4β2 Nicotinic Acetylcholine Receptor Partial Agonist, vs Sustained-Release Bupropion and Placebo for Smoking Cessation<SUBTITLE>A Randomized Controlled Trial</SUBTITLE>
Abstract
CONTEXT: The alpha4beta2 nicotinic acetylcholine receptors (nAChRs) are linked to the reinforcing effects of nicotine and maintaining smoking behavior. Varenicline, a novel alpha4beta2 nAChR partial agonist, may be beneficial for smoking cessation. OBJECTIVE: To assess efficacy and safety of varenicline for smoking cessation compared with sustained-release bupropion (bupropion SR) and placebo. DESIGN, SETTING, AND PARTICIPANTS: Randomized, double-blind, parallel-group, placebo- and active-treatment-controlled, phase 3 clinical trial conducted at 19 US centers from June 19, 2003, to April 22, 2005. Participants were 1025 generally healthy smokers (> or =10 cigarettes/d) with fewer than 3 months of smoking abstinence in the past year, 18 to 75 years old, recruited via advertising. INTERVENTION: Participants were randomly assigned in a 1:1:1 ratio to receive brief counseling and varenicline titrated to 1 mg twice per day (n = 352), bupropion SR titrated to 150 mg twice per day (n = 329), or placebo (n = 344) orally for 12 weeks, with 40 weeks of nondrug follow-up. MAIN OUTCOME MEASURES: Primary outcome was the exhaled carbon monoxide-confirmed 4-week rate of continuous abstinence from smoking for weeks 9 through 12. A secondary outcome was the continuous abstinence rate for weeks 9 through 24 and weeks 9 through 52. RESULTS: For weeks 9 through 12, the 4-week continuous abstinence rates were 44.0% for varenicline vs 17.7% for placebo (odds ratio [OR], 3.85; 95% confidence interval [CI], 2.70-5.50; P<.001) and vs 29.5% for bupropion SR (OR, 1.93; 95% CI, 1.40-2.68; P<.001). Bupropion SR was also significantly more efficacious than placebo (OR, 2.00; 95% CI, 1.38-2.89; P<.001). For weeks 9 through 52, the continuous abstinence rates were 21.9% for varenicline vs 8.4% for placebo (OR, 3.09; 95% CI, 1.95-4.91; P<.001) and vs 16.1% for bupropion SR (OR, 1.46; 95% CI, 0.99-2.17; P = .057). Varenicline reduced craving and withdrawal and, for those who smoked while receiving study drug, smoking satisfaction. No sex differences in efficacy for varenicline were observed. Varenicline was safe and generally well tolerated, with study drug discontinuation rates similar to those for placebo. The most common adverse events for participants receiving active-drug treatment were nausea (98 participants receiving varenicline [28.1%]) and insomnia (72 receiving bupropion SR [21.9%]). CONCLUSION: Varenicline was significantly more efficacious than placebo for smoking cessation at all time points and significantly more efficacious than bupropion SR at the end of 12 weeks of drug treatment and at 24 weeks. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00141206.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Varenicline, a nicotinic acetylcholine receptor (nAChR) partial agonist, is reported to increase continuous abstinence rates to ∼50% following 12 weeks of treatment, which is significantly better than bupropion (∼30%) or placebo (∼18%”
From Parallel Anxiolytic-Like Effects and Upregulation of Neuronal Nicotinic Acetylcholine Receptors Following Chronic Nicotine and Varenicline (2011) · cites this paper as Gonzales et al., 2006
In the citing paper
“Varenicline, a partial agonist at the α4β2 nAChRs, and a full agonist at the α7 nAChRs, is a new, efficacious treatment for nicotine dependence (4–6).”
From Varenicline improves mood and cognition during smoking abstinence (2009) · cites this paper as [4]
In the citing paper
“These trials document treatment-related reductions in smoking urges and withdrawal-related negative affect (4, 5, 9), as well as reduced smoking reward during a lapse (10).”
From Varenicline improves mood and cognition during smoking abstinence (2009) · cites this paper as [4]
In the citing paper
“The effects of varenicline on subjective abstinence symptoms were of a magnitude similar to those observed in clinical efficacy trials (4, 36).”
From Varenicline improves mood and cognition during smoking abstinence (2009) · cites this paper as [4]
In the citing paper
“Individuals who relapsed derived less enjoyment from smoking while taking varenicline [241].”
From Mechanistic insights into nicotine withdrawal (2011) · cites this paper as [241]
In the citing paper
“Nearly one quarter (21–23%) of patients taking varenicline for a short period of time (12 weeks) maintained abstinence at 52 weeks of follow-up.”
From Mechanistic insights into nicotine withdrawal (2011) · cites this paper as [241]
In the citing paper
“Gonzales and colleagues [241] found a similar decrease in negative affect, but also found a significant decrease in restlessness in patients taking varenicline.”
From Mechanistic insights into nicotine withdrawal (2011) · cites this paper as [241]
In the citing paper
“This represents a significant improvement over sustained-release bupropion (14–16%) and placebo (8–10%).”
From Mechanistic insights into nicotine withdrawal (2011) · cites this paper as [241]
In the citing paper
“Two large, randomized, placebo-controlled studies released in 2006 related the efficacy of varenicline to that of bupropion in aided smoking cessation [233, 241].”
From Mechanistic insights into nicotine withdrawal (2011) · cites this paper as [241]
In the citing paper
“numerous studies have shown that varenicline, a Food and Drug Administration-approved drug widely used to help people quit smoking, potently acts as a partial agonist at ␣42* nAChRs”
From Varenicline Is a Potent Partial Agonist at α6β2* Nicotinic Acetylcholine Receptors in Rat and Monkey Striatum (2012) · cites this paper as Gonzales et al., 2006
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. B. (2013) · Oxford University Press eBooks · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,845
The Fagerstrom Test for Nicotine Dependence: a revision of the Fagerstrom Tolerance Questionnaire
HEATHERTON, T. F., KOZLOWSKI, L. T., FRECKER, R. C., & FAGERSTROM, K. (1991) · British Journal of Addiction · doi:10.1111/j.1360-0443.1991.tb01879.x · Cited by 10,738
Signs and Symptoms of Tobacco Withdrawal
Hughes, J. R. (1986) · Archives of General Psychiatry · doi:10.1001/archpsyc.1986.01800030107013 · Cited by 1,669
A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation
Jorenby, D. E., Leischow, S. J., Nides, M. A., Rennard, S. I., Johnston, J. A., Hughes, A. R., Smith, S. S., Muramoto, M. L., Daughton, D. M., Doan, K., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199903043400903 · Cited by 1,585
Cigarette Smoking Among Adults--United States, 2003
(2005) · JAMA · doi:10.1001/jama.294.2.172 · Cited by 1,520
Cox, L. S., Tiffany, S. T., & Christen, A. G. (2001) · Nicotine & Tobacco Research · doi:10.1080/14622200020032051 · Cited by 1,188
Effects of nicotine on the nucleus accumbens and similarity to those of addictive drugs.
Pontieri, F. E., Tanda, G., Orzi, F., & Chiara, G. D. (1996) · Nature · doi:10.1038/382255a0 · Cited by 1,073
Jasinski, D. R. (1978) · Archives of General Psychiatry · doi:10.1001/archpsyc.1978.01770280111012 · Cited by 782
Fiore, M. (2000) · Respiratory care · doi:10.1177/002013240004501006 · Cited by 773
Cited by
Sorted by citations
Items 801–900 of 1,000
Bedell, S., Wells, J. R., Liu, Q., & Breivogel, C. S. (2019) · Pharmaceutical Biology · doi:10.1080/13880209.2018.1561725 · Cited by 11
Treatment strategies for peripheral artery disease
McCann, A. B., & Jaff, M. R. (2009) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560902988502 · Cited by 11
Gepner, A. D., Piper, M. E., Leal, M. A., Asthana, A., Fiore, M. C., Baker, T. B., & Stein, J. H. (2013) · PLoS ONE · doi:10.1371/journal.pone.0062311 · Cited by 11
Huber, G. L., & Mahajan, V. K. (2008) · Disease Management & Health Outcomes · doi:10.2165/0115677-200816050-00010 · Cited by 11
Patel, P. D., & Arora, R. R. (2010) · American Journal of Therapeutics · doi:10.1097/mjt.0b013e3181727d06 · Cited by 11
Use of Varenicline in Smokeless Tobacco Cessation: A Systematic Review and Meta-Analysis
Schwartz, J., Fadahunsi, O. O., Hingorani, R., Mainali, N. R., Oluwasanjo, A., Aryal, M. R., & Donato, A. A. (2015) · Nicotine & Tobacco Research · doi:10.1093/ntr/ntv010 · Cited by 11
Brandon, T. H., Unrod, M., Drobes, D. J., Sutton, S. K., Hawk, L. W., Simmons, V. N., Brandon, K. O., Roetzheim, R. G., Meltzer, L. R., Miller, R. R., et al. (2017) · Nicotine & Tobacco Research · doi:10.1093/ntr/ntx203 · Cited by 11
More than Smoke and Patches: The Quest for Pharmacotherapies to Treat Tobacco Use Disorder
Moerke, M. J., McMahon, L. R., & Wilkerson, J. L. (2020) · Pharmacological Reviews · doi:10.1124/pr.119.018028 · Cited by 11
Svendsen, M., Heggen, E., Klemsdal, T. O., & Tonstad, S. (2021) · Clinical Obesity · doi:10.1111/cob.12447 · Cited by 11
Benowitz, N. L., & Brunetta, P. G. (2010) · Elsevier eBooks · doi:10.1016/b978-1-4160-4710-0.00040-7 · Cited by 11
Maximizing Smoking Cessation in Clinical Practice: Pharmacologic and Behavioral Interventions
Nides, M. A., Leischow, S. J., Sarna, L., & Evans, S. E. (2007) · Preventive Cardiology · doi:10.1111/j.1520-037x.2007.05992.x · Cited by 11
Arabi, Z. (2007) · Southern Medical Journal · doi:10.1097/smj.0b013e3180f631ad · Cited by 11
Qin, R., Liu, Z., Cheng, A., Zhou, X., Su, Z., Cui, Z., Li, J., Wei, X., Zhao, L., Chung, K. F., et al. (2024) · Respirology · doi:10.1111/resp.14702 · Cited by 10
Conditions of sleep restoration after smoking cessation: A systematic review
Mauries, S., Rolland, B., Mallevays, M., Catoire, S., Zehani, F., Sauvage, K., Davido, G., Lejoyeux, M., & Geoffroy, P. A. (2024) · Sleep Medicine Reviews · doi:10.1016/j.smrv.2024.102041 · Cited by 10
Update on Peripheral Arterial Disease and Claudication Rehabilitation
Salameh, M., & Ratchford, E. V. (2009) · Physical Medicine and Rehabilitation Clinics of North America · doi:10.1016/j.pmr.2009.06.004 · Cited by 10
Continued Smoking in Lung Transplant Patients: A Cross Sectional Survey
Zmeškal, M., Králíková, E., Kurcová, I., Pafko, P., Lischke, R., Fila, L., Bartakova, L. V., & Fraser, K. (2015) · Slovenian Journal of Public Health · doi:10.1515/sjph-2016-0005 · Cited by 10
Lawson, S. C., Gass, J. C., Cooper, R. K., Tonkin, S., Colder, C. R., Mahoney, M. C., Tiffany, S. T., & Hawk, L. W. (2020) · Psychopharmacology · doi:10.1007/s00213-020-05713-7 · Cited by 10
5-HT2A and 5-HT2C receptors as potential targets for the treatment of nicotine use and dependence
Higgins, G. A., & Sellers, E. M. (2021) · Progress in brain research · doi:10.1016/bs.pbr.2021.01.007 · Cited by 10
Attenuating nicotine’s effects with high affinity human anti-nicotine monoclonal antibodies
Raleigh, M. D., Beltraminelli, N., Fallot, S., LeSage, M. G., Saykao, A. T., Pentel, P. R., Fuller, S., Thisted, T., Biesova, Z., Horrigan, S. K., et al. (2021) · PLoS ONE · doi:10.1371/journal.pone.0254247 · Cited by 10
Palumbo, T. B., & Miwa, J. M. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106845 · Cited by 11
Caponnetto, P., Spicuzza, L., Campagna, D., Ahluwalia, J. S., Russell, C., Maglia, M. G., Riela, P. M., Longo, F., Caci, G., Quattropani, M. C. A., et al. (2023) · EClinicalMedicine · doi:10.1016/j.eclinm.2023.102316 · Cited by 10
Growth Mindset as a Predictor of Smoking Cessation
Johnson, V. D. (2009) · EngagedScholarship @ Cleveland State University (Cleveland State University) · Cited by 10
Office Management of COPD in Primary Care: A 2009 Clinical Update
Belfer, M. H. (2009) · Postgraduate Medicine · doi:10.3810/pgm.2009.07.2034 · Cited by 10
A brief 7-day estimate of alcohol consumption for use in smoking cessation clinical trials
Toll, B. A., Leeman, R. F., McKee, S. A., & O’Malley, S. S. (2008) · Addictive Behaviors · doi:10.1016/j.addbeh.2008.07.007 · Cited by 10
Pharmacotherapy for tobacco cessation: Nicotine agonists, antagonists, and partial agonists
Karam‐Hage, M., & Cinciripini, P. M. (2007) · Current Oncology Reports · doi:10.1007/s11912-007-0072-6 · Cited by 10
Smoking Cessation Interventions for Lung Cancer Patients
Carson‐Chahhoud, K., Usmani, Z. A., Robertson, T. A., Mysore, S., & Brinn, M. P. (2013) · Lung Cancer Management · doi:10.2217/lmt.12.55 · Cited by 11
Olano-Espinosa, E., Minué-Lorenzo, C., & Ayesta, F. J. A. (2010) · Medicina Clínica · doi:10.1016/j.medcli.2010.05.017 · Cited by 10
Current Treatment Options in Smoking Cessation
Crain, D., & Bhat, A. (2010) · Hospital Practice · doi:10.3810/hp.2010.02.279 · Cited by 11
Clinical experience of varenicline for smoking cessation
Jung, J., Jeon, E. J., Kim, J. G., Yang, S., Choi, J. C., Shin, J. W., Park, I. W., Choi, B. W., Kim, D., & Kim, J. Y. (2009) · The Clinical Respiratory Journal · doi:10.1111/j.1752-699x.2009.00178.x · Cited by 10
Nakamura, M., Abe, M., Ohkura, M., Treadow, J., Yu, C., & Park, P. W. (2017) · Clinical Therapeutics · doi:10.1016/j.clinthera.2017.03.007 · Cited by 10
Ali, R., Zhang, Z., & Soomro, M. B. (2019) · Current Psychology · doi:10.1007/s12144-019-00479-4 · Cited by 10
Smoking Addiction and Strategies for Cessation
DiSilvio, B. E., Baqdunes, M. W., Alhajhusain, A., & Cheema, T. J. (2020) · Critical Care Nursing Quarterly · doi:10.1097/cnq.0000000000000338 · Cited by 11
Stapleton, J. (2009) · Addiction · doi:10.1111/j.1360-0443.2009.02567.x · Cited by 10
Correa, J. B., Heckman, B. W., Marquinez, N. S., Drobes, D. J., Unrod, M., Roetzheim, R. G., & Brandon, T. H. (2014) · Psychopharmacology · doi:10.1007/s00213-013-3420-2 · Cited by 10
The influence of acute varenicline administration on smoking and eating behavior in humans
Stoops, W. W., Vansickel, A. R., Glaser, P. E. A., & Rush, C. R. (2008) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2008.07.001 · Cited by 10
Correlates of Continued Tobacco Use and Intention to Quit Smoking Among Russian Cancer Patients
Schnoll, R. A., Subramanian, S., Martinez, E., & Engstrom, P. F. (2010) · International Journal of Behavioral Medicine · doi:10.1007/s12529-010-9131-8 · Cited by 10
Yang, M., Chen, H., Johnson, M. L., Essien, E. J., Peters, R. J., Wang, X., & Abughosh, S. (2016) · Substance Use & Misuse · doi:10.3109/10826084.2015.1126744 · Cited by 11
Roig, L., Pérez, S. T., Prieto, G., Martín-Cantera, C., Advani, M., Armengol, A., Roura, P., Manresa‐Domínguez, J. M., Briones, E., & ITADI Study Group (2010) · BMC Public Health · doi:10.1186/1471-2458-10-58 · Cited by 10
How to implement a smoke-free policy
Cormac, I., & McNally, L. M. (2008) · Advances in Psychiatric Treatment · doi:10.1192/apt.bp.107.004069 · Cited by 10
Wenner, F., & Goedken, J. A. (2012) · Postgraduate Obstetrics & Gynecology · doi:10.1097/01.pgo.0000419579.75781.7a · Cited by 10
Role of the Neuregulin Signaling Pathway in Nicotine Dependence and Co-morbid Disorders
Fisher, M. L., Loukola, A., Kaprio, J. A., & Turner, J. R. (2015) · International review of neurobiology · doi:10.1016/bs.irn.2015.07.006 · Cited by 10
Ansiedad, depresión y deshabituación tabáquica.
Pacheco, V. A., Gómez-Bastero, A., Morales, A. S. V., Crespo, E. L., Monserrat, S., & Rubio, T. M. (2016) · Adicciones · doi:10.20882/adicciones.761 · Cited by 10
Sun, Y., Duan, W., Xin, M., Li, H., & Jia, C. (2017) · Journal of Public Health · doi:10.1093/pubmed/fdx056 · Cited by 10
Itani, T., Rai, D., Jones, T., Taylor, G. M. J., Thomas, K. H., Martin, R. M., Munafo, M. R., Davies, N. M., & Taylor, A. E. (2019) · Scientific Reports · doi:10.1038/s41598-019-54727-5 · Cited by 10
The effect of varenicline on mood and cognition in smokers with HIV
Thompson, M., Schnoll, R. A., Serrano, K., Leone, F. T., Gross, R., Collman, R. G., & Ashare, R. L. (2020) · Psychopharmacology · doi:10.1007/s00213-020-05451-w · Cited by 10
Strategies for smoking cessation: what is new and what works?
Cummings, K. M., & Mahoney, M. C. (2008) · Expert Review of Respiratory Medicine · doi:10.1586/17476348.2.2.201 · Cited by 10
Chronic Obstructive Pulmonary Disease in the Older Patient
Nazir, S. A., Alhamed, M., & Erbland, M. L. (2007) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2007.07.003 · Cited by 10
Challenges and perspectives of tobacco cessation in special groups of patients and populations
Tsikrika, S., Dai, S., Dilektaşlı, A. G., Katsaounou, P. A., & Dağlı, E. (2023) · Breathe · doi:10.1183/20734735.0224-2022 · Cited by 9
The smoking cessation drug varenicline improves deficient P20–N40 inhibition in DBA/2 mice
Wildeboer, K. M., & Stevens, K. E. (2011) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2011.07.001 · Cited by 9
Managing cardiovascular risk factors: Trial evidence in women
Hsia, J. A. (2010) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2010.01.010 · Cited by 9
Patel, A. R., Panchal, J. R., & Desai, C. K. (2023) · Indian Journal of Psychiatry · doi:10.4103/indianjpsychiatry.indianjpsychiatry_218_22 · Cited by 10
Fang, H., Dong, T., Li, S., Zhang, Y., Han, Z., Liu, M., Dong, W., Zheng, H., Fu, M., & Zhang, H. (2023) · International Journal of COPD · doi:10.2147/copd.s425735 · Cited by 9
Russell, R. E. K., Ford, P., & Barnes, P. J. (2011) · doi:10.1007/978-1-908517-61-6_6 · Cited by 9
Lee, J.-Y., Kim, M. J., Jun, H.-J., Kang, M., Park, A.-R., Oh, D. E., Choi, Y.-H., & Hwang, J. H. (2012) · Tuberculosis & respiratory diseases · doi:10.4046/trd.2012.72.5.426 · Cited by 9
Update on smoking cessation therapies
Glynn, D. A., Cryan, J. F., Kent, P., Flynn, R. A., & Kennedy, M. P. (2009) · Advances in Therapy · doi:10.1007/s12325-009-0022-9 · Cited by 9
Hsueh, S.-C., Hsueh, K.-C., Chou, M.-Y., & Tu, M. (2012) · Evaluation & the Health Professions · doi:10.1177/0163278712466868 · Cited by 9
Updates in the management of stable chronic obstructive pulmonary disease
Narsingam, S., Bozarth, A. L., & Abdeljalil, A. (2015) · Postgraduate Medicine · doi:10.1080/00325481.2015.1084212 · Cited by 9
Hall, B. J., Pearson, L. S., & Buccafusco, J. J. (2009) · Neuropharmacology · doi:10.1016/j.neuropharm.2009.09.009 · Cited by 9
The Neurobiology of Nicotine Addiction: Clinical and Public Policy Implications
Gardner, P. D., Tapper, A. R., King, J. A., DiFranza, J. R., & Ziedonis, D. M. (2009) · Journal of Drug Issues · doi:10.1177/002204260903900211 · Cited by 9
Update on the pharmacologic therapy for chronic obstructive pulmonary disease.
Hanania, N., & Sharafkhaneh, A. (2007) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2007.06.007 · Cited by 18
Silverstone, P. H., & Dadashova, R. (2012) · Annals of General Psychiatry · doi:10.1186/1744-859x-11-6 · Cited by 9
Cui, Y., Robinson, J. D., Engelmann, J. M., Lam, C. Y., Minnix, J. A., Karam‐Hage, M., Wetter, D. W., Dani, J. A., Kosten, T. R., & Cinciripini, P. M. (2015) · Psychology of Addictive Behaviors · doi:10.1037/adb0000050 · Cited by 9
Sigara bırakma başarısını etkileyen faktörler
BERKEŞOĞLU, Ç., Özgür, E. S., & Demır, A. U. (2018) · Mersin üniversitesi sağlık bilimleri dergisi/Mersin üniversitesi sağlık bilimleri dergisi · doi:10.26559/mersinsbd.473902 · Cited by 9
Zincir, S. B., Zincir, S., Kaymak, E., & Sünbül, E. A. (2013) · Klinik Psikofarmakoloji Bülteni-Bulletin of Clinical Psychopharmacology · doi:10.5455/bcp.20130313045037 · Cited by 9
Effects of ceftriaxone on conditioned nicotine reward in rats
Philogene-Khalid, H. L., Simmons, S. J., Muschamp, J. W., & Rawls, S. M. (2017) · Behavioural Pharmacology · doi:10.1097/fbp.0000000000000314 · Cited by 9
Smoking cessation in cardiovascular patients.
Stefanatou, A. (2008) · PubMed · Cited by 9
The up-rise in e-cigarette use – friend or foe?
Lundbäck, B., Katsaounou, P. A., & Lötvall, J. O. (2016) · Respiratory Research · doi:10.1186/s12931-016-0371-2 · Cited by 9
The Persistent Challenge of Developing Addiction PharmacotherapiesPreprint
Swinford-Jackson, S. E., O’Brien, C. P., Kenny, P. J., Vanderschuren, L. J. M. J., Unterwald, E. M., & Pierce, R. C. (2020) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a040311 · Cited by 10
Varenicline plus Healthy Lifestyle Intervention for Smoking Cessation in Psychotic Disorders
Castle, D. J., Baker, A., RICHMOND, R. L., Filia, S., Harris, D., & Pirola‐Merlo, A. (2012) · Annals of Clinical Psychiatry · doi:10.1177/104012371202400406 · Cited by 8
It's about time – directing our attention toward modifying the course of COPD
Cazzola, M., Hanania, N. A., Jones, P., Mahler, D. A., Make, B. J., Ohar, J. A., & Rennard, S. I. (2008) · Respiratory Medicine · doi:10.1016/s0954-6111(08)70006-4 · Cited by 8
Chen, L., Baker, T. B., Ramsey, A. T., Amos, C. I., & Bierut, L. J. (2023) · Addiction Neuroscience · doi:10.1016/j.addicn.2023.100083 · Cited by 8
Mann, K. F., Berner, M. M., & Günthner, A. (2012) · Elsevier eBooks · doi:10.1016/b978-3-437-22483-6.10009-9 · Cited by 8
Diagnosis, Prevention, and Treatment of Claudication
Knepper, J. P., & Henke, P. K. (2013) · Surgical Clinics of North America · doi:10.1016/j.suc.2013.04.005 · Cited by 8
2013 Update in addiction medicine for the generalist
Gordon, A. J., Bertholet, N., McNeely, J., Starrels, J. L., Tetrault, J. M., & Walley, A. Y. (2013) · Addiction Science & Clinical Practice · doi:10.1186/1940-0640-8-18 · Cited by 8
Koga, M., Kanaoka, Y., Sugiyama, K., Ohishi, K., Ejima, Y., Hisanaga, M., Kataoka, Y., & Yamauchi, A. (2017) · Toxicology · doi:10.1016/j.tox.2017.08.006 · Cited by 8
Distress Tolerance and Craving for Cigarettes Among Heavy Drinking Smokers
Lim, A. C., Roche, D. J. O., & Ray, L. A. (2018) · Journal of Studies on Alcohol and Drugs · doi:10.15288/jsad.2018.79.918 · Cited by 8
Galiatsatos, P., Garfield, J. L., Melzer, A. C., Leone, F. T., Farber, H. J., Ruminjo, J. K., & Thomson, C. C. (2020) · Annals of the American Thoracic Society · doi:10.1513/annalsats.202008-971cme · Cited by 8
Dopaminergic involvement in effort-based but not impulsive reward processing in smokers
Freeman, T. P., Morgan, C. J. A., Brandner, B., Almahdi, B., & Curran, H. V. (2012) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2012.10.016 · Cited by 8
Emerging drugs for the treatment of tobacco dependence
Ebbert, J. O. (2009) · Expert Opinion on Emerging Drugs · doi:10.1517/14728210802623874 · Cited by 8
Jiang, B., He, Y., Zuo, F., Wu, L., Liu, Q., Zhang, L., Zhou, C., Cheng, K. K., Chan, S. S. C., & Lam, T. H. (2016) · BMJ Open · doi:10.1136/bmjopen-2015-009381 · Cited by 8
Proposals for the prevention of lung cancer in the health system of Mexico
Arrieta, O. G., López-Mejía, M., Macedo-Pérez, E. O., & Corona-Cruz, J. F. (2016) · Salud Pública de México · doi:10.21149/spm.v58i2.7796 · Cited by 9
Wind, L., Chavannes, N. H., Kaper, J., Frijling, B. D., van der Laan, J. R., Wiersma, T., & Goudswaard, A. N. (2008) · PubMed · Cited by 8
Tanigawa, T., Nomura, A., Kuroda, M., Muto, T., Hida, E., & Satake, K. (2019) · JMIR Research Protocols · doi:10.2196/12701 · Cited by 8
Hsueh, K.-C., Tang, P., & McRobbie, H. J. (2021) · Nicotine & Tobacco Research · doi:10.1093/ntr/ntab018 · Cited by 9
Chronic obstructive pulmonary disease and smoking: prevention principles and ways: a review
Gambaryan, M. G., & Drapkina, O. M. (2017) · Russian Journal of Preventive Medicine · doi:10.17116/profmed201720574-82 · Cited by 8
Diffuse exanthema in a patient receiving varenicline
Song, W. Y., & Miller, W. A. (2008) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp070458 · Cited by 8
Dubey, S., & Powell, C. A. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200702-190up · Cited by 8
Nicotine Discrimination in Humans
Perkins, K. A. (2011) · Wiley eBooks · doi:10.1002/9781118023150.ch15 · Cited by 8
Smoking Cessation: The Urgent Need for Increased Utilization of Varenicline
Gaballa, D., Drowos, J. L., & Hennekens, C. H. (2016) · The American Journal of Medicine · doi:10.1016/j.amjmed.2016.11.015 · Cited by 8
Edzamba, M. F., Cheuyem, F. Z. L., Amani, A., & Mossus, T. (2024) · American Journal of Biomedical Science & Research · doi:10.34297/ajbsr.2024.21.002812 · Cited by 7
Mifepristone decreases nicotine intake in dependent and non-dependent adult rats
Chellian, R., Behnood‐Rod, A., & Bruijnzeel, A. W. (2024) · Journal of Psychopharmacology · doi:10.1177/02698811241230255 · Cited by 7
Translational Approaches to Medication Development
Bartlett, S. E., & Heilig, M. A. (2011) · Current topics in behavioral neurosciences · doi:10.1007/978-3-642-28720-6_132 · Cited by 7
Park, P. W., Casiano, E. M., Escoto, L., & Claveria, A. M. (2011) · Current Medical Research and Opinion · doi:10.1185/03007995.2011.607436 · Cited by 7
NHG-Standaard Stoppen met roken
Chavannes, N. H., Kaper, J., Frijling, B. D., der Laan, J. V., Jansen, P., Guerrouj, S., Drenthen, A. J. M., Bax, W. A., & Wind, L. (2011) · Bohn Stafleu van Loghum eBooks · doi:10.1007/978-90-313-8279-8_52 · Cited by 7
Medications Development for the Treatment of Nicotine Dependence in Individuals with Schizophrenia
Montoya, I. D., & Vocci, F. J. (2007) · Journal of Dual Diagnosis · doi:10.1300/j374v03n03_09 · Cited by 7
Kropff, B., Petersilka, G., Flemmig, T., Ehmke, B., Heuft, G., & Schneider, G. (2015) · International Journal of Dental Hygiene · doi:10.1111/idh.12124 · Cited by 9
Behavioral Interventions in Tobacco Dependence
Leone, F. T., & Evers‐Casey, S. (2009) · Primary Care Clinics in Office Practice · doi:10.1016/j.pop.2009.04.002 · Cited by 7
Nicotine- and cocaine-triggered methamphetamine reinstatement in female and male Sprague-Dawley rats
Pittenger, S. T., Chou, S., Barrett, S. T., Catalano, I., Lydiatt, M. F., & Bevins, R. A. (2017) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2017.07.003 · Cited by 7
Roberts, W., Ralevski, E., Verplaetse, T. L., McKee, S. A., & Petrakis, I. L. (2018) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2018.08.015 · Cited by 7
Photochemical Degradation of Organic Xenobiotics in Natural Waters
Klementová, Š. (2018) · InTech eBooks · doi:10.5772/intechopen.74756 · Cited by 7
Metadata
- Authors
- Gonzales, D.
- Affiliations
- Oregon Health & Science University (US)
- Corresponding author
- Gonzales, David
- ORCID
- Gonzales, David
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2006-07-05
- Volume
- 296
- Issue
- 1
- Pages
- 47
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2107200746
- Cited by
- 1,361
- References
- 29
- Citations by year
- 2026: 32 · 2025: 21 · 2024: 25 · 2023: 25 · 2022: 34 · 2021: 26 · 2020: 52 · 2019: 49 · 2018: 41 · 2017: 51 · 2016: 50 · 2015: 70 · 2014: 74 · 2013: 80 · 2012: 94
- FWCI
- 85.72
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- JAMA (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Oregon Health and Science University
- Cardinal Health
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Smoking Behavior and Cessation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nicotinic Acetylcholine Receptors Study
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Keywords
- varenicline, bupropion sustained release, smoking cessation, α4β2 nicotinic acetylcholine receptor, partial agonists, nicotine dependence, continuous abstinence, exhaled carbon monoxide, brief counseling, nicotine replacement therapy, drug safety, adverse events, relapse, nicotine withdrawal symptoms, nicotine self-administration
- MeSH terms
- Varenicline, Adult, Benzazepines, Delayed-Action Preparations, Double-Blind Method, Female, Humans, Male, Middle Aged, Quinoxalines, Receptors, Nicotinic, Smoking Cessation, Bupropion, Nicotinic Agonists, Dopamine Uptake Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
